Body Fat Distribution and Its Associated Factors in Chinese Women With Polycystic Ovary Syndrome

September 23, 2021 updated by: Peking University Third Hospital

Department of Traditional Chinese Medicine (TCM), Center for Reproductive Medicine, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing 100191, China.

To investigate the body fat distribution in chinese women with polycystic ovary syndrome (PCOS) and the association of those distribution with metabolic parameters, microeconomics, hormone profiles and psychological state.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in women of reproductive age. It is also one of the leading causes of anovulatory infertility and secondary amenorrhea, which represent major stress factors in the female life. In the previous studies, the investigators found that PCOS patients showed decreased quality-of-life and increased psychological disturbances compared with healthy controls. Body mass index (BMI) was associated with emotional disorders and physical aspects of quality-of-life and negative emotions were negatively correlated with BMI in PCOS patients.These results prompted that PCOS could be separated into at least two subtypes by the fat content. So the investigators expand the epidemiological investigation for comparing the body composition between the PCOS and the normal women, and finding specific biological indicators in different subtypes.

Study Type

Observational

Enrollment (Actual)

733

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100191
        • Peking University Third Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

a cross-sectional study was conducted in women of reproductive age (19- 45 years) from the Peking university third hospital

Description

Inclusion Criteria:

  • Age 18 to 45 years
  • For the PCOS group, PCOS diagnosis according to Rotterdam criteria 2003 with at least two of the following three symptoms: (1) infrequent ovulation or anovulation; (2) hyperandrogenism or clinical manifestations of high blood androgen; (3) ultrasound findings of polycystic ovaries in 1 or 2 ovaries, or ≥12 follicles measuring 2 to 9 mm in diameter, and/or ovarian volume ≥10 mL

Exclusion Criteria:

  • Exclusion of other endocrine disorders such as androgen secreting tumors, suspected Cushing's syndrome and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone < 3nmol/L) thyroid dysfunction and hyperprolactinemia.
  • Type I diabetes or not well controlled type II diabetes
  • Stage 2 hypertension (resting blood pressure ≥160/100mmHg)
  • Psychiatric diagnoses or using psychiatric medications including antidepressants
  • Pharmacological treatment (cortizone, antidepressant, other antidiabetic treatment such as insulin and acarbose, hormonal contraceptives, hormonal ovulation induction or other drugs judged by discretion of investigator) within 12 weeks. Depo Provera or similar within 6 months.

The control group are non- PCOS normal women (age 18-45) and meet the same exclusion criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
observation group
Participants were eligible if they met the Rotterdam diagnostic criteria of polycystic ovary syndrome (PCOS) and meet the inclusion and exclusion criteria , and all study participants received questionnaires and underwent the physical, transvaginal ultrasound and body composition examination. Blood samples were collected for analysis of metabolic markers, metabonomics and hormones.

Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).

A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.

Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.

Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS), self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life .

control group
The control group participants are normal women and had no history of any type of diabetes, cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization), stage 2 hypertension , malignant disease or severe renal or hepatic disease. They accepted the same examinations as the observation group.

Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).

A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.

Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.

Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS), self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life .

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
body fat content and ratio
Time Frame: Baseline
Examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan)
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body mass index (BMI)
Time Frame: Baseline
Weight in kilograms divided by the square of height in meters, reported in kg/m2
Baseline
Waist circumference(WC)
Time Frame: Baseline
Waist circumference(WC)reported in cm, refers to the horizontal circumference along the midpoint of the connection line of the anterior superior iliac crest through the lower costal margin of the calm breathing state when standing. Recumbent position is the abdominal circumference through the girth of the navel.
Baseline
Hip circumference
Time Frame: Baseline
Hip circumference reported in cm, and when measured, the legs are upright and closed together, the arms are naturally pendulous, and the tape measure is placed horizontally on the pubic symphysis in front and the gluteus maximus in the back.
Baseline
Waist-hip ratio (WHR)
Time Frame: Baseline
Waist-to-hip ratio
Baseline
Fat content and ratio of trunk
Time Frame: Baseline
Examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan)
Baseline
Follicle stimulating hormone (FSH)
Time Frame: Baseline
Examined with the blood sample
Baseline
luteinizing hormone (LH)
Time Frame: Baseline
Examined with the blood sample
Baseline
Progestin (P)
Time Frame: Baseline
Examined with the blood sample
Baseline
Estrogen (E2)
Time Frame: Baseline
Examined with the blood sample
Baseline
Prolactin (PRL)
Time Frame: Baseline
Examined with the blood sample
Baseline
Androgen(T)
Time Frame: Baseline
Examined with the blood sample
Baseline
Androstenedione (A2)
Time Frame: Baseline
Examined with the blood sample
Baseline
Glucose
Time Frame: Baseline
Examined with the blood sample
Baseline
Insulin
Time Frame: Baseline
Examined with the blood sample
Baseline
HOMA-IR
Time Frame: Baseline
calculation of HOMA-IR: [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5)
Baseline
HOMA- β
Time Frame: Baseline
calculation of HOMA-β: 20 × fasting insulin (mU/mL) / (fasting plasma glucose (mmol/L) - 3.5) (%)
Baseline
total cholesterol
Time Frame: Baseline
examined with the blood sample
Baseline
triglycerides
Time Frame: Baseline
examined with the blood sample
Baseline
high density lipoprotein (HDL)
Time Frame: Baseline
examined with the blood sample
Baseline
low density lipoprotein (LDL)
Time Frame: Baseline
examined with the blood sample examined with the blood sample
Baseline
β-endorphin
Time Frame: Baseline
examined with the blood sample
Baseline
5- hydroxytryptamine (5-HT)
Time Frame: Baseline
examined with the blood sample
Baseline
Dopamine(DA)
Time Frame: Baseline
examined with the blood sample
Baseline
lipometabonomics
Time Frame: Baseline
examined with the blood sample
Baseline
bile acid
Time Frame: Baseline
examined with the blood sample (fasting plasma glucose (mmol/L) - 3.5) (%)
Baseline
FerrimanGallwey (FG )value
Time Frame: Baseline
To determine changes in women's hairy with FG rating scale (0-36 score), the higher, the worse
Baseline
short form-36 (SF36)
Time Frame: Baseline
determine the health quality of life by the questionnaire of SF36 (0-100 score), the higher, the better
Baseline
Self-Rating Anxiety Scale (SAS)
Time Frame: Baseline
determine the anxiety level with the questionnaire of SAS (20-100 score), the higher, the worse.
Baseline
Self-Rating Depress Scale (SDS)
Time Frame: Baseline
determine the depress level with the questionnaire of SDS (20-100 score), the higher, the worse
Baseline
Preserved Stress Scale (PSS)
Time Frame: Baseline
determine the stress level with the questionnaire of SDS (14-56 score), the higher, the worse
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Haolin Zhang, Peking University Third Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2016

Primary Completion (Actual)

May 1, 2021

Study Completion (Actual)

September 1, 2021

Study Registration Dates

First Submitted

February 7, 2020

First Submitted That Met QC Criteria

February 7, 2020

First Posted (Actual)

February 11, 2020

Study Record Updates

Last Update Posted (Actual)

September 29, 2021

Last Update Submitted That Met QC Criteria

September 23, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

We haven't decided whether to share the data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovary Syndrome (PCOS)

Clinical Trials on Clinical data collection

3
Subscribe